ELVN insider transactions
Enliven Therapeutics Inc. (ELVN) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
ELVN insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Enliven Therapeutics Inc., latest first. Follow anyone to get their next filing.
- Lori Anne KunkelDirector, since April 2024-$850K
- J. Scott GarlandDirector, since January 2026
- Benjamin HohlChief Financial Officer, since February 2023-$4.51M
- Helen Louise CollinsChief Medical Officer, since February 2023-$4.71M
- Richard A. HeymanDirector, since February 2023-$1.09M
- Mika K DerynckDirector, since February 2023-$9.56M
- Orbimed Advisors LLC10% owner+$20M-$74.6M
- The Biotech Growth Trust PLCDirector
- Rishi GuptaDirector, since February 2023-$22.9M
- Jake BauerDirector, since February 2023
- Rahul D. BallalDirector-$2.44M
- Anish PatelChief Operating Officer, since February 2023-$5.9M
- Joseph P LyssikatosChief Scientific Officer, since February 2023-$11.8M
- Richard A. FairPresident and CEO, Director, since December 2025
- Samuel KintzPresident and CEO, Director, since February 2023-$7.24M
- Andrew John PhillipsDirector, since February 2023
- 5AM Partners VI, LLC10% owner-$29.8M
- Andrew J. SchwabDirector, 10% owner, since February 2023
- Commodore Capital LP10% owner, since February 2023+$177K
- Ra Capital Management, L.P.Insider, since October 2022+$4.83M
- Michael GrayOfficer-$60.1K
- Braden Michael Leonard10% owner, since April 2022+$965K-$10.4M
- Laura A WilliamsDirector, since June 2021
- Carl GoldfischerDirector
- Barbara DaltonDirector
- Edward R. ConnerDirector
- Mark ChinDirector+$8M
- David P BonitaDirector, 10% owner+$20M
- David M MottDirector+$314K
- New Enterprise Associates 14, L.P.10% owner-$2.27M
- Kenneth AttieOfficer, since January 2021
- Sara M. NayeemDirector
Recent Form 3, 4, and 5 filings for ELVN
- Director Kunkel Lori Anne exercised 11,041 shares at a strike of $12.48, increasing direct ownership by 26% to 52,925 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin sold $231,546 worth of shares (6,018 units at $38.48) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF MEDICAL OFFICER Collins Helen Louise sold $192,342 worth of shares (5,000 units at $38.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Enliven Therapeutics Inc.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 3 filed by Enliven Therapeutics Inc.3 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Director Garland J. Scott sold $606,719 worth of shares (13,000 units at $46.67) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,982 shares at a strike of $14.85 and sold $303,003 worth of shares (6,018 units at $50.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 38,000 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $251,754 worth of shares (5,000 units at $50.35) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin sold $352,551 worth of shares (6,018 units at $58.58) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 40,036 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $292,931 worth of shares (5,000 units at $58.59) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Director Derynck Mika K exercised 158,795 shares at a strike of $10.84 and sold $9,561,587 worth of shares (158,795 units at $60.21) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin sold $316,780 worth of shares (6,018 units at $52.64) as part of a pre-agreed trading plan and exercised 1,072 shares at a strike of $2.48, decreasing direct ownership by 10% to 46,054 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $263,373 worth of shares (5,000 units at $52.67) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Director Kunkel Lori Anne sold $504,903 worth of shares (10,000 units at $50.49) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 41,884 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Large owner Orbimed Advisors Llc sold $39,014,046 worth of shares (860,123 units at $45.36) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 6,018 shares at a strike of $2.48 and sold $263,577 worth of shares (6,018 units at $43.80) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF MEDICAL OFFICER Collins Helen Louise sold $219,017 worth of shares (5,000 units at $43.80) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $2.48 (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Large owner Orbimed Advisors Llc sold $12,668,988 worth of shares (281,408 units at $45.02) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Director Kunkel Lori Anne sold $345,351 worth of shares (10,000 units at $34.54) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 51,884 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF MEDICAL OFFICER Collins Helen Louise sold $198,971 worth of shares (5,000 units at $39.79) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $2.48 (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Enliven Therapeutics Inc.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin sold $295,839 worth of shares (10,000 units at $29.58), decreasing direct ownership by 16% to 51,000 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Director Heyman Richard A. sold $32,196 worth of shares (1,230 units at $26.18) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF MEDICAL OFFICER Collins Helen Louise exercised 45,000 shares at a strike of $2.48 and sold $1,177,862 worth of shares (45,000 units at $26.17) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Director Kunkel Lori Anne4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Director Heyman Richard A.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Director Gupta Rishi4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Director Garland J. Scott4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Director Derynck Mika K4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Director Bauer Jake4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Director Ballal Rahul D.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF OPERATING OFFICER Patel Anish was granted 20,000 shares (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P was granted 18,750 shares (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin was granted 25,000 shares, increasing direct ownership by 69% to 61,000 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF MEDICAL OFFICER Collins Helen Louise was granted 25,000 shares (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $145,219 worth of shares (5,000 units at $29.04) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $535,099 worth of shares (20,000 units at $26.75) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Director Heyman Richard A. sold $32,902 worth of shares (1,230 units at $26.75) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF OPERATING OFFICER Patel Anish sold $1,351,762 worth of shares (48,300 units at $27.99) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $3,476,014 worth of shares (132,500 units at $26.23) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Director Heyman Richard A. sold $348,281 worth of shares (13,920 units at $25.02) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by Director Garland J. Scott4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 3 filed by new insider Garland J. Scott3 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 13,000 shares at a strike of $2.48, increasing direct ownership by 57% to 36,000 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $84,206 worth of shares (5,000 units at $16.84) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- Director Kunkel Lori Anne exercised 15,958 shares at a strike of $1.12, increasing direct ownership by 108% to 30,712 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 4 filed by PRESIDENT AND CEO Fair Richard A.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SEC Form 3 filed by new insider Fair Richard A.3 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF OPERATING OFFICER Patel Anish sold $140,073 worth of shares (6,663 units at $21.02) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $279,155 worth of shares (12,500 units at $22.33) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- PRESIDENT AND CEO Kintz Samuel sold $272,739 worth of shares (12,500 units at $21.82) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF OPERATING OFFICER Patel Anish sold $116,034 worth of shares (6,667 units at $17.40) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $276,025 worth of shares (12,500 units at $22.08) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- PRESIDENT AND CEO Kintz Samuel sold $266,654 worth of shares (12,500 units at $21.33) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF OPERATING OFFICER Patel Anish sold $133,993 worth of shares (6,667 units at $20.10) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $66,291 worth of shares (3,250 units at $20.40) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $81,005 worth of shares (4,000 units at $20.25) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)